Alan Musso
Director of Finance/CFO bei FULCRUM THERAPEUTICS, INC.
Vermögen: - $ am 31.03.2024
Profil
Alan A.
Musso is currently serving as an Independent Director at Aileron Therapeutics, Inc., Chief Financial Officer & Treasurer at Fulcrum Therapeutics, Inc., and Chief Financial & Accounting Officer at OS Therapies, Inc. Previously, he held positions as Director-Finance & Accounting at Teva Women's Health, Inc., Director at Lung Therapeutics LLC, General Accounting Manager-Barceloneta Region at Pfizer Inc., Chief Financial Officer & Vice President at Osiris Therapeutics, Inc., Chief Financial Officer & Treasurer at Bellicum Pharmaceuticals, Inc., Chief Financial Officer at Peloton Therapeutics, Inc., Chief Financial Officer at Vascular Genetics, Inc., Chief Financial Officer at Cato Research LLC, CFO, Treasurer, SVP-Finance & Administration at Targacept, Inc., and Chief Financial Officer at ReViral.
Mr. Musso obtained a graduate degree from Thunderbird School of Global Management in 2008 and an undergraduate degree from St. Mary's College of California in 1984.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.01.2024 | 0 ( -.--% ) | - $ | 31.03.2024 | |
| 30.11.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Alan Musso
| Unternehmen | Position | Beginn |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Director of Finance/CFO | 07.08.2023 |
| AILERON THERAPEUTICS, INC. | Director/Board Member | 31.10.2023 |
OS Therapies, Inc.
 OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | Director of Finance/CFO | 01.03.2023 |
Ehemalige bekannte Positionen von Alan Musso
| Unternehmen | Position | Ende |
|---|---|---|
Lung Therapeutics, Inc.
 Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Director/Board Member | 31.10.2023 |
ReViral
 ReViral BiotechnologyHealth Technology ReViral is a clinical-stage biopharmaceutical company that develops novel antiviral therapeutics. The private company is based in Durham, NC. | Director of Finance/CFO | 01.09.2022 |
| PELOTON THERAPEUTICS, INC. | Director of Finance/CFO | 01.09.2019 |
| BELLICUM PHARMACEUTICALS, INC. | Director of Finance/CFO | 31.08.2018 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Director of Finance/CFO | 01.11.2014 |
Ausbildung von Alan Musso
| Thunderbird School of Global Management | Graduate Degree |
| St. Mary's College of California | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| AILERON THERAPEUTICS, INC. | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Teva Women's Health, Inc.
 Teva Women's Health, Inc. Pharmaceuticals: MajorHealth Technology Teva Women's Health, Inc. produces a wide range of women’s healthcare products. Its products include oral contraceptives, intrauterine contraception, and hormone therapy treatments for menopause. The company is headquartered in Woodcliff Lake, NJ. | Health Technology |
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Health Technology |
| Vascular Genetics, Inc. | Health Technology |
Cato Research LLC
 Cato Research LLC Miscellaneous Commercial ServicesCommercial Services Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC. | Commercial Services |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | Commercial Services |
ReViral
ReViral BiotechnologyHealth Technology ReViral is a clinical-stage biopharmaceutical company that develops novel antiviral therapeutics. The private company is based in Durham, NC. | Health Technology |
